Gossamer Bio’s Post

Exciting revelations emerge from the PANTS study three year extension data published in The Lancet on #CrohnsDisease. The study used IDKmonitor TDM assays to assess the efficacy of #infliximab and #adalimumab, revealing that only a third of patients are in sustained remission at three years, and low serum drug levels at week 14 and 52 predict non-remission in years 2 and 3, highlighting the importance of #TherapeuticDrugMonitoring. For more insights, read the full paper here: https://ow.ly/Cehi50RjJ5W

🌟 Join Us for an Exclusive Webinar! 🌟 📅 June 12, 2024 💻 Online Webinar Dive into the latest trends in Pharma and IP & Genetic Resources and Traditional Knowledge with AIPPI Committees! Learn from experts and stay ahead in IP. 🔗 Register now! #AIPPI #Webinar #Pharma #IP #GeneticResources #TraditionalKnowledge For more info, visit AIPPI website

Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and multiple doses, meeting its primary safety endpoints and showed early signs of potential efficacy.1  DMI is a common, irreversible complication of diabetic retino... https://buff.ly/4abidBG Boehringer Ingelheim today presented positive data from the HORNBILL Phase I/IIa study of BI 764524, the first ever study exploring a potential treatment for people living with diabetic macular ischemia (DMI). The study found that BI 764524 was well tolerated following intravitreal administration of single and multiple doses, meeting its primary safety endpoints and showed early signs of potential efficacy.1  DMI is a common, irreversible complication of diabetic retino... #pharma #biotech #lifesciences #clinicalresearch #news #pharmiweb

𝗨𝘀𝘁𝗲𝗸𝗶𝗻𝘂𝗺𝗮𝗯 𝗠𝗮𝗿𝗸𝗲𝘁 𝟮𝟬𝟮𝟰-𝟮𝟬𝟯𝟬. 𝗚𝗹𝗼𝗯𝗮𝗹 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝗥𝗲𝗽𝗼𝗿𝘁 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/d8XYD3dy The report offers an in-depth examination of the Ustekinumab industry chain development, market status across various medical conditions such as Arthritis and Colitis, and profiles key enterprises in both established and emerging markets. Cutting-edge technologies, patents, applications, and market trends related to Ustekinumab are analyzed. Regionally, North America and Europe show steady growth propelled by governmental initiatives and rising consumer awareness, while Asia-Pacific, particularly China, leads the global market with strong domestic demand, supportive policies, and robust manufacturing capabilities. Providing a comprehensive overview, the report delves into market dynamics, trends, challenges, and opportunities within the Ustekinumab industry, offering holistic insights into its various components and stakeholders. 𝗧𝗼 𝗞𝗻𝗼𝘄 𝗗𝗲𝗺𝗮𝗻𝗱 𝗼𝗳 𝗨𝘀𝘁𝗲𝗸𝗶𝗻𝘂𝗺𝗮𝗯 𝗠𝗮𝗿𝗸𝗲𝘁. 𝗥𝗲𝗾𝘂𝗲𝘀𝘁 𝗳𝗼𝗿 𝗦𝗮𝗺𝗽𝗹𝗲 𝗣𝗗𝗙: https://lnkd.in/d8XYD3dy *𝗕𝘆 𝗧𝘆𝗽𝗲: Intravenous, Subcutaneous *𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Colitis, Lupus Erythematosus, Myositis Multiplex With Palmoplantar Pustulosis, Cirrhosis Of The Liver, Sarcoidosis, Diabetes, Other *𝗕𝘆 𝗥𝗲𝗴𝗶𝗼𝗻: North America, Europe, Asia-Pacific, South America, Middle East & Africa *𝗕𝘆 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Johnson & Johnson, Alvotech, Fuji Pharma Co. Ltd., Mitsubishi Tanabe Pharma America, STADA Group, Formycon AG, NeuClone, Outlook Therapeutics, Inc., Harvest Moon Pharmaceuticals, BioXpress Therapeutics #Ustekinumab #ArthritisTreatment #ColitisRelief #BiologicTherapy #ChronicDiseaseManagement #InflammatoryConditions #MedicalInnovation #HealthcareAdvancements #PatientCare #PharmaceuticalIndustry

In a recent MarketWatch article, CIO Yuri Khodjamirian, CFA sheds light on Novo Nordisk's strategic advancements in the obesity treatment market in light of positive clinical trial results for oral Amycretin. "This strengthens Novo's portfolio, ensuring their leadership in the field with successors to Ozempic/Wegovy, such as Cagrisema and Amycretin," he states. A promising future for Novo's obesity franchise as it innovates beyond patent expirations. Read the full article: https://hubs.ly/Q02nyRht0 #NovoNordisk #Obesity #Pharma #ETFs

The CAGR of the #Glycomicsmarket is projected to be 13.5% from 2024 to 2031. Growing #biopharmaceuticalindustry and rising research & development investments and personalized #medicine and increasing #diagnostics demand are the major factors driving the growth of the glycomics market. Dive into a detailed #marketanalysis @ https://rb.gy/fa6in9

🦠 Gut Dysbiosis refers to an imbalance of bacteria in your gut which can lead to a wide range of health issues. Luckily, Nucliq Biologics is doing what they can to address Canadians' problems with gut health. GutcheckTM Analysis unravels your unique gut microbiome and helps you get to the source of the problem! 🔗 Check out mygutcheck.ca to learn more about their gut kit, or head to nucliqbio.ca to learn more about Nucliq Biologics! #BounceHealthInnovation #BouncePartner #NucliqBiologics #GutCheck #HealthTechNL

IPD Analytics has released its semiannual Biosimilar Pipeline Report. The report for 1H 2024 provides an outlook for potential approvals and launches across the biosimilar landscape over the 2024–2027 horizon. In addition, the report examines trends in average sales prices (ASPs) of both reference products and biosimilar products that have ASPs. As utilization of biosimilars has increased, we have noted a trend of decreasing ASPs; certain reference products have experienced dramatic decreases, including Herceptin (29%), Neulasta Onpro (81%), and Remicade (63%). Subscribers can use this report as a companion to our online Clinical Development Tracker within our Payer & Provider Insights platform, which provides up-to-date clinical pipeline information on thousands of products across various disease classes and therapeutic areas. In tandem, these reports deliver insight into trending classes that will affect the competitive landscape and drug spend. Read it now: https://lnkd.in/ePB3rxY #humira #enbrel #remicade #simponi #cimzia #stelara #xolair #actemra #entyvio #prolia #novolog #lantus #soliris #tysabri #herceptin #rituxan #ocrevus #avastin #eylea #lucentis #neulasta #neupogen #biosimilars #drugpricing

Though it feels like we've been talking about biosimilars for years (because we have), these markets are still very much in their early stages. With so many interesting launches on the horizon over the next few years, understanding not only what products will launch, but also how the commercial and pricing dynamics are developing will be critical.

Unlock the future of biosimilars with IPD Analytics' 1H 2024 Biosimilar Pipeline Report. Explore potential approvals, launches, and ASP trends. Don't miss insights on PBM Drug Exclusion Lists for 2024 and Trend Reports on generics. Stay ahead in pharmaceuticals – register now! #IPDAnalytics #PharmaInsights